HighTide Therapeutics, Inc.

  • About Us
    • Leadership
    • Contact
  • Our Focus
    • Overview
    • MASH
    • SHTG
    • Type 2 Diabetes
    • Obesity
    • PSC
  • Science
    • Pipeline
    • Berberine Ursodeoxycholate
    • Discovery Portfolio
    • Scientific Publications
    • Expanded Access Policy
  • News
  • Investors
  • Culture & Careers
    • Culture
    • Open Positions
  • Language
    • 中文

News

HighTide Therapeutics invited to present at the World Orphan Drug Congress USA 2019

Jeffrey Dao, Operations & Business Development Officer to present HighTide’s HTD1801 for primary sclerosing cholangitis (PSC) at the World Orphan Drug Congress USA 2019 in Oxon Hill, MD

©2025 HighTide Therapeutics, Inc.

  • Terms of Use
  • Privacy Policy
MENU
  • About Us
    • Leadership
    • Contact
  • Our Focus
    • Overview
    • MASH
    • SHTG
    • Type 2 Diabetes
    • Obesity
    • PSC
  • Science
    • Pipeline
    • Berberine Ursodeoxycholate
    • Discovery Portfolio
    • Scientific Publications
    • Expanded Access Policy
  • News
  • Investors
  • Culture & Careers
    • Culture
    • Open Positions
  • Language
    • 中文